| Patient | Pablo Neruda |
|---|---|
| Date of birth | 1959-07-12 |
| Identifiers | MRN HR-ML051-SYN; SSN (made up) 000-51-2976 |
| Document date | 2026-10-05 |
| Author | Marisol Fairweather-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Subsequent annual wellness visit; no new complaints. [S]
Mr. Neruda returns for his subsequent annual wellness visit, with a professional Spanish interpreter; his first was with his previous physician last year. He completed the health risk assessment in Spanish beforehand. He is three weeks past his second leuprolide injection and continues apalutamide; radiotherapy to the prostate finished six weeks ago. The rash has gone. Hot flashes come four or five times a day and wake him once or twice a night; he would rather not take a medicine for them yet. His energy is lower in the afternoons, and he rests after lunch. He has no bone pain, has had no falls, and walks most afternoons. He writes every morning and has kept his official duties, apart from a week of engagements put off during radiotherapy. His interest in sex has fallen, as he was told it might; he has thought about it and does not want treatment for it now. [S]
| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit |
| Safety events | No falls, emergency visits or hospital stays in the past year; one sick visit for a drug rash |
| Medicines | Leuprolide 22.5 mg every twelve weeks; apalutamide 240 mg daily; amlodipine 10 mg daily; cholecalciferol 2000 units daily; denosumab 60 mg every six months |
| Active conditions | Metastatic hormone-sensitive prostate cancer on androgen deprivation with apalutamide; hypertension; prediabetes; low bone mass |
| Functional status | Independent in all activities and instrumental activities of daily living |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Fair to good |
| Psychosocial | Writing every morning; close to his wife and friends; worry about the cancer at times, manageable |
| Tobacco | Never used tobacco |
| Alcohol and drugs | Wine with dinner a few evenings a week (AUDIT-C 2); no other drug use |
| Physical activity | Walks 30 minutes most afternoons; light resistance exercise twice a week, begun for bone and muscle on androgen deprivation |
| Nutrition | Many official dinners; dairy, fish and greens for calcium; weight up 2.2 kg since starting treatment |
| Sleep | Hot flashes wake him once or twice a night; rests after lunch |
| Activities of daily living | Independent |
| Instrumental activities of daily living | Independent; manages his own medicines with a weekly pill box |
| Home safety | Smoke detectors working; rugs secured; good lighting on the stairs |
| Falls | No falls; no fear of falling |
| Hearing and vision | Reading glasses; eye examination last year; hearing good |
| Memory | No concerns |
| Pain | None |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Lower afternoon energy on androgen deprivation; weight up 2.2 kg; no fever or night sweats |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Negative | No hearing change; no mouth sores |
| Cardiovascular | Negative | No chest pain, palpitations or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | Bowels back to normal after radiotherapy; no bleeding |
| Genitourinary | Positive | Nocturia once; stream better; lower libido and erections |
| Musculoskeletal | Negative | No bone or joint pain |
| Integumentary | Negative | Rash resolved |
| Neurological | Negative | No weakness, numbness or unsteadiness |
| Psychiatric | Negative | Mood steady; PHQ-2 score 0 |
| Endocrine | Positive | Hot flashes four or five times a day; no breast tenderness |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-04-06 to 2026-07-13 | completed | S |
| Amlodipine 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-07-13 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain | Two tablets up to three times daily as needed | Oral route | 2026-06-01 to 2026-09-14 | completed | S |
| Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food | One tablet once daily | Oral route | 2026-06-15 | active | S |
| Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeks | One injection every twelve weeks | Intramuscular route | 2026-06-22 | active | S |
| Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-15 | active | S |
| Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivation | One injection every six months | Subcutaneous route | 2026-07-13 | active | S |
| Triamcinolone acetonide 0.1% cream, apply a thin layer to the rash twice daily for two weeks (not the face or groin) | Twice daily for two weeks | Topical route | 2026-08-10 to 2026-08-24 | completed | S |
| Cetirizine 10 mg oral tablet, one tablet daily for itch | One tablet daily | Oral route | 2026-08-10 to 2026-08-31 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-10-05 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-05 | Body height | 178 | cm | S |
| 2026-10-05 | Body weight | 94.6 | kg | S |
| 2026-10-05 | Body mass index (BMI) [Ratio] | 29.9 | kg/m2 | S |
| 2026-10-05 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-10-05 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-05 | Heart rate | 70 | /min | S |
| 2026-10-05 | Respiratory rate | 14 | /min | S |
| 2026-10-05 | Body temperature | 36.6 | Cel | S |
| 2026-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-05 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-05 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2026-10-05 | Total score [AUDIT-C] | 2 | {score} | S |
Vital signs recorded on 2026-10-05; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well and engaged; weight 94.6 kg, BMI 29.9; blood pressure 128/78 |
| Eyes | Near vision 20/30 with reading glasses |
| Ears | Whispered-voice test passed on both sides |
| Neck | No thyroid enlargement; no lymph nodes |
| Cardiovascular | Regular rhythm at 70 per minute; no murmur; no ankle swelling |
| Respiratory | Clear |
| Chest | Mild gynecomastia without tenderness |
| Abdomen | Soft and non-tender |
| Musculoskeletal | No spinal or pelvic tenderness; Timed Up and Go 9 seconds; rises from a chair without using his arms |
| Neurological | Strength and sensation normal in the legs; gait steady; Mini-Cog 5 of 5 |
| Psychiatric | Euthymic, thoughtful; judgment and insight intact |
| Skin | Rash resolved without scarring; no suspicious lesions |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmed | resolved | confirmed | R97.20 | S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer. |
| Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1971 | active | confirmed | C61 | S — Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read. |
| Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compression | active | confirmed | C79.51 | S — Synthetic metastatic sites. |
| Pelvic lymph node metastases: right external iliac and right obturator nodes | active | confirmed | C77.5 | S — Synthetic nodal disease. |
| Hormone-sensitive prostate cancer | active | confirmed | Z19.1 | S — Synthetic status in the modern episode. |
| Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognition | active | confirmed | Z79.899 | S — Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy. |
| Essential hypertension for five years, on amlodipine | active | confirmed | I10 | S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure. |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding at intake, addressed at the second visit. |
| Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis) | active | confirmed | M85.89 | S — Synthetic bone-health finding on the DXA before androgen deprivation. |
| Prediabetes (hemoglobin A1c 5.9%) | active | confirmed | R73.03 | S — Synthetic metabolic finding at intake, relevant to androgen deprivation. |
| Maculopapular drug rash from apalutamide, grade 2 (about 20 percent of body surface, trunk and upper arms), eight weeks into treatment; no mucosal involvement, blistering, fever, eosinophilia or liver involvement; settled on topical steroid and an antihistamine without stopping apalutamide | resolved | confirmed | L27.0 | S — Synthetic intercurrent problem at an unscheduled visit; a known effect of apalutamide, not a historical claim. |
| Personal history of radiotherapy to the prostate (55 Gy in 20 fractions, finished three weeks before the three-month visit) | active | confirmed | Z92.3 | S — Synthetic: recorded after the course of radiotherapy finished. |
| Raised TSH (5.4 mIU/L) with a normal free T4 on apalutamide: subclinical, under observation | active | confirmed | R94.6 | S — Synthetic finding; raised TSH is a known effect of apalutamide. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine | Completed today | High-dose vaccine given today |
| COVID-19 vaccine | Completed today | This season's vaccine given today |
| Pneumococcal vaccine | Completed today | PCV20 given today; no earlier pneumococcal vaccine; no further doses needed |
| Recombinant zoster vaccine | Due | Never given; dose 1 at the next visit, as he wanted no more than three injections today |
| RSV vaccine | Not indicated | Under 75 without a chronic heart, lung, kidney or immune condition that raises his risk; to be reviewed at 75 or if that changes |
| Tetanus, diphtheria and pertussis booster | Up to date | Tdap six years ago; next in four years |
| Colorectal cancer screening | Up to date | Normal colonoscopy seven years ago; next due in three years |
| Abdominal aortic aneurysm screening | Not indicated | Recommended for men 65 to 75 who have ever smoked; he never smoked |
| Lung cancer screening | Not indicated | Never smoker |
| Hepatitis C screening | Up to date | One-time screening negative eight years ago |
| Cholesterol and statin decision | Completed today | 10-year ASCVD risk about 17 percent; atorvastatin 20 mg started after discussion |
| Diabetes screening | Up to date | Hemoglobin A1c 6.1 percent three weeks ago (prediabetes); repeat yearly on androgen deprivation |
| Bone density | Up to date | DXA four months ago; denosumab every six months; repeat DXA in one to two years |
| Depression screening | Completed today | PHQ-2 score 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 2, low risk |
| Cognitive assessment | Completed today | Mini-Cog 5 of 5 |
| Falls prevention | Completed today | Timed Up and Go 9 seconds; no falls; apalutamide raises fall risk, so resistance and balance exercise continue |
| Skin check | Completed today | No suspicious lesions |
Immunizations given today: High-dose influenza vaccine, this season; COVID-19 vaccine, mRNA, this season; Pneumococcal conjugate vaccine PCV20 [S]
Guideline basis: CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022); Adult Immunization Schedule by Age (2026)
Follow-up: Zoster vaccine dose 1 and blood pressure check in six weeks, with a lipid panel, ALT, TSH and free T4. Medical oncology and the next leuprolide injection in nine weeks. Next annual wellness visit in one year. [S]
Voluntary advance care planning discussion of about 30 minutes, in Spanish with a professional interpreter, with his consent. He named a health care agent, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is to keep writing, to be told the truth about his illness in his own language, and to make his own decisions. He chose not to record specific treatment preferences today and will review the plan with his oncologist and with this clinic yearly or if his health changes. [S]